Powering the Path of New Therapies From Lab to Patient
How Baird Capital’s investment in Blue Matter helps fuel healthcare innovation.
Developing a new therapy is the first step, but turning those breakthroughs into real-life patient impact is just as critical. That’s where Blue Matter comes in. The life sciences consulting firm works with both emerging biotech companies and leading pharmaceutical organizations, helping them make strategic decisions that bring life-saving therapies from the lab to patients – particularly in oncology and rare diseases.
Baird Capital first invested in Blue Matter in 2020. Since then, the business has more than tripled in revenue. Through a continuation fund and a new investment from Baird Capital’s most recent global fund, Baird has now extended that investment – bringing in new investors to support growth in areas like technology, patient services and other capabilities that connect patients with life-saving treatments.
Learn more about how Baird makes a difference.
